The leader in quality education and networking through//conferences, courses and custom training
Connect with IBC Life Sciences:LinkedIn iconTwitter iconFacebook iconRSS icon
EmailPrint

TIDES: Oligonucleotide and Peptide Therapeutics from Research through Commercialization

CSS

Agenda CSS

Access the hottest fields in therapeutics by attending TIDES - the only event with full coverage of discovery, development and manufacturing

May 12-15, 2014
Rhode Island Convention Center
Providence, RI

Alt Language

Alternative Language Options:

  • Japanese
  • Korean
  • Taiwanese
  • Chinese

Scientific Advisory Boards

Scientific Advisory Boards

Scientific Advisory Boards

For Oligonucleotide and Peptide Manufacturing Technology and Product Development Track

Kathryn L. Ackley, Ph.D., RAC, Senior Director Cincinnati Operations, Nitto Denko Avecia Inc.

Firoz Antia, Ph.D., CMC Team Director, Pharmaceutical Operations and Technology, Biogen Idec

Mimoun Ayoub, Ph.D., Vice President, Global Peptides and Injectables, Corden Pharma

Neil H. Baine, Ph.D., Past Executive Director, Scinovo, Preclinical Development, GlaxoSmithKline Pharmaceuticals (Retired)

Doug Brooks, Ph.D., Vice President, Manufacturing Development, Ophthotech Corporation

Bob D. Brown, Ph.D., Chief Scientific Officer and Senior Vice President, Research, Dicerna Pharmaceuticals

Alex Fässler, Ph.D., President and COO, Bachem Americas Inc.

Peter Hoffmann, Ph.D.

David Litzinger, Ph.D., President, David Litzinger and Associates, LLC

John P. Mayer, Ph.D., Senior Research Scientist, Department of Chemistry, Indiana University

Paul McCormac, Ph.D., Director, Biomanufacturing Sciences Group, Pfizer Global Manufacturing

Michael McGinley, Bioseparations Product Manager, Phenomenex

Bruce Morimoto, Ph.D., Executive Director Applied Translational Medicine, Drug Development Services, Celerion

Gary F. Musso, Ph.D., President, Musso and Associates LLC

Lubomir V. Nechev, Ph.D., Vice President, Process Chemistry, Alnylam Pharmaceuticals, Inc.

El Djouhar Rekaï, Head of Peptide Products Operation, Lonza, Belgium

Claus Rentel, Ph.D., Executive Director, Analytical Development Quality Control, Isis Pharmaceuticals

Christopher A. Rhodes, Ph.D., President, Christopher A. Rhodes & Associates LLC

Christoph Rosenbohm, Ph.D., Senior Director, Research Operations, Santaris Pharma A/S, Denmark

Trishul Shah, Key Account Manager, Business Development, North America, PolyPeptide Laboratories

G. Susan Srivatsa, Ph.D., President, ElixinPharma

James D. Thompson, Ph.D., Head, Process Sciences, Moderna Therapeutics, Inc.

David Tumelty, Ph.D., Director of Chemistry, New England Peptide

Blake Unterreiner, Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc.

Fran Wincott, Ph.D., President, Wincott & Associates, LLC

For Oligonucleotide Therapeutics Discovery Track

David Brown, Ph.D., Director of Research, Mirna Therapeutics, Inc.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, Quark Pharmaceuticals, Israel

Troels Koch, Ph.D., Vice President, Research and CTO, Santaris Pharma A/S, Denmark

Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

Pamela Pavco, Ph.D., Chief Development Officer, RXi Pharmaceuticals

For Peptide Discovery and Development Track

Jesse Dong, Ph.D., Vice President, Compound Discovery, IPSEN

Tomi Sawyer, Ph.D., Past-Founding CSO, Aileron Therapeutics and Adjunct Professor, University of Massachusetts and Northeastern University

Peter Timmerman, Ph.D., Chief Scientific Officer, Pepscan Therapeutics, The Netherlands

Thomas Vorherr, Ph.D., Director Peptide Discovery, Novartis Pharma AG, Switzerland

Paul Watt, Ph.D., CEO, Phylogica Ltd., Australia

skyline